The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: A global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines

Supportive Care in Cancer

Volumn 16, Issue 2, 2008, Pages 193-200

  Aapro, Matti ^a   Abraham, Ivo ^b,c   Bokemeyer, Carsten ^d   Ludwig, Heinz ^e   MacDonald, Karen ^b   Soubeyran, Pierre ^f   Turner, Matthew ^g  

^a Multidisciplinary Oncology Institute   (Switzerland)

^b Matrix45 ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e WILHELMINEN HOSPITAL   (Austria)

^f INSTITUT BERGONIÉ   (France)

^g ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Anaemia; Cancer; Erythropoiesis stimulating agent; Retrospective

Indexed keywords

ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PATIENT; CANCER RESEARCH; COLON CANCER; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; HEAD AND NECK CANCER; HEALTH SURVEY; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD; MYELOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WORLD HEALTH;

EID: 38349187596     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0311-2     Document Type: Article

References (32)

1. Aapro M, Abraham I, MacDonald K et al (2007) Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision-support system for supportive cancer care. Support Care Cancer http://dx.doi.org/10.1007/s00520-007-0246-7
2. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V (2003) Assessment and management of cancer-related fatigue in adults. Lancet 362:640-650
3. Andrews NC (2004) Anemia of inflammation: the cytokine hepcidin link. J Clin Invest 113:1251-1253
4. Birgegård G, Aapro MS, Bokemeyer C et al (2005) Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68(Suppl 1):3-11
5. Bokemeyer C, Aapro MS, Courdi A et al (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201-2216
6. Bokemeyer C, Oechsle K, Hartmann JT (2005) Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest 35(Suppl 3):26-31
7. Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258-270
8. Boogaerts M, Coiffier B, Kainz C, Epoetin Beta QOL Working Group (2003) Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88:988-995
9. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214-2221
10. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25(3 Suppl 7):43-46
11. Curt GA, Breitbart W, Cella D et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5:353-360
12. Eddy DM (2005) Evidence-based medicine: a unified approach. Health Aff (Millwood) 24:9-17
13. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP (1999) Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 340:438-447
14. Hedenus M, Adriansson M, San Miguel J et al; Darbepoetin Alfa 20000161 Study Group (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394-403
15. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR; Ferrlecit Cancer Study Group (2004) Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy-results of a multicenter, randomized trial. Blood 104:3696 (abstract)
16. Jackson R, Feder G (1998) Guidelines for clinical guidelines. BMJ 317:427-428
17. Kreft I, De Leeuw J (1998) Introducing multilevel modeling. Sage Publications, London
18. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B; Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
19. Locatelli F, Aljama P, Bárány P et al; European Best Practice Guidelines Working Group (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19(Suppl 2):ii1-ii47
20. Ludwig H, Fritz E, Kotzmann H et al (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693-1699
21. Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anaemia Study (ECAS): a large, multinational, prospective study defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293-2306
22. Österborg A (1998) Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned. Med Oncol 15(Suppl 1):S47-S49
23. Österborg A, Brandberg Y, Molostova V et al; Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20:2486-2494
24. Rizzo JD, Lichtin AE, Woolf SH et al; American Society of Clinical Oncology. American Society of Hematology (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107
25. Rosser WW, Davis D, Gilbart E (2001) Assessing guidelines for use in family practice. J Fam Pract 50:969-973
26. Sandler SG, Yu H, Rassai N (2003) Risks of blood transfusion and their prevention. Clin Adv Hematol Oncol 1:307-313
27. Spaeth D, Casadevall N, Daouphars M et al; Standards, Options and Recommendations project (2004) Summary version of the standards, options and recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology-update 2003. Bull Cancer 91(2):179-188
28. Thomas ML (1998) Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Med Oncol 15(Suppl 1):S3-S7
29. Timmermans S, Mauck A (2005) The promises and pitfalls of evidence-based medicine. Health Aff (Millwood) 24:18-28
30. Turner R, Anglin P, Burkes R et al; Canadian Cancer and Anemia Guidelines Development Group (2001) Epoetin alfa in cancer patients: evidence-based guidelines. J Pain Symptom Manage 22(5):954-965
31. Van Belle S, Paridaens R, Evers G et al (2005) Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. Support Care Cancer 13:246-254
32. Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment study. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4-12